Skip to main content

An initial dosing method for teicoplanin based on the area under the serum concentration time curve required for MRSA eradication

Abstract

Teicoplanin is a glycopeptide antibacterial agent that has a long serum half-life and therefore takes time to achieve steady-state conditions. An appropriate initial dosing is needed for teicoplanin to promptly reach an effective serum trough concentration. However, little information is available on tailoring the initial dosing for patients with various characteristics. The objective of this study was to develop a nomogram for determining teicoplanin initial dose to promptly reach an effective trough concentration (≥13 μg/mL). A logistic regression analysis was performed to test whether the area under the concentration time curve (AUC) is a significant predictor of microbiological response (persistence 0; eradication 1). The study included 24 adult patients with methicillin-resistant Staphylococcus aureus infections [minimal inhibitory concentration (MIC) for the isolates was <2 μg/mL). Each AUC was estimated using individual dose, creatinine clearance (CLcr), and body weight data. The target value, which gives about a 0.9 microbiological eradication probability, was 750 μg h/mL for AUC from zero to 24 h (AUC0–24 h). Using published population pharmacokinetic parameters, the dose required to achieve the AUC0–24 h target was calculated as dose (mg) = 750 × (0.00498 × CLcr (mL/min) + 0.00426 × body weight (kg). For various combinations of CLcr and body weight, we checked the calculated doses using a therapeutic drug monitoring (TDM)-supporting software and developed a nomogram. The nomogram would be useful for initial dose adjustment to promptly reach an effective serum trough concentration and avoid adverse events of teicoplanin.

This is a preview of subscription content, access via your institution.

Fig. 1

References

  1. MacGowan AP, White LO, Reeves DS, Harding I. Retrospective review of serum teicoplanin concentrations in clinical trials and their relationship to clinical outcome. J Infect Chemother. 1996;2:197–208.

    Article  Google Scholar 

  2. MacGowan AP. Pharmacodynamics, pharmacokinetics, and therapeutic drug monitoring of glycopeptides. Ther Drug Monit. 1998;20:473–7.

    PubMed  Article  CAS  Google Scholar 

  3. Kollef MH. Optimizing antibiotic therapy in the intensive care unit setting. Crit Care. 2001;5:189–95.

    PubMed  Article  CAS  Google Scholar 

  4. Niederman MS. Appropriate use of antimicrobial agents: challenges and strategies for improvement. Crit Care Med. 2003;31:608–16.

    PubMed  Article  Google Scholar 

  5. Arakawa S, Yamashita K, Li M, et al. Effective use of teicoplanin for MRSA infections in surgical patients. Jpn Soc Environ Infect. 2006;21:17–23.

    Google Scholar 

  6. Matsumoto K, Kanazawa N, Ikawa K, et al. Determination of teicoplanin trough concentration target and appropriate total dose during the first 3 days: a retrospective study in patients with MRSA infections. J Infect Chemother. 2010; 16:193–199.

    Google Scholar 

  7. Kuti JL, Kiffer CR, Mendes CM, Nicolau DP. Pharmacodynamic comparison of linezolid, teicoplanin and vancomycin against clinical isolates of Staphylococcus aureus and coagulase-negative staphylococci collected from hospitals in Brazil. Clin Microbiol Infect. 2008;14:116–23.

    PubMed  Article  CAS  Google Scholar 

  8. Nakayama K, Gemma H, Kaibara A, Niwa T. Population pharmacokinetics of teicoplanin in adult patients. Jpn J Chemother. 2006;54:1–6.

    CAS  Google Scholar 

  9. Wilson AP. Clinical pharmacokinetics of teicoplanin. Clin Pharmacokinet. 2000;39:167–83.

    PubMed  Article  CAS  Google Scholar 

  10. Sato M, Chida K, Suda T, et al. Recommended initial loading dose of teicoplanin, established by therapeutic drug monitoring, and outcome in terms of optimal trough level. J Infect Chemother. 2006;12:185–9.

    PubMed  Article  CAS  Google Scholar 

  11. Sugawara M, Yamasawa Y, Saito K, Kobayashi M, Tanaka H, Tadano K. The assessment of MRSA infection remedy based on therapeutic monitoring of teicoplanin. Jpn J Ther Drug Monit. 2008;25:28–36.

    Google Scholar 

  12. Miyagoe T, Matsumoto K, Oiso S, Shimodozono Y, Takeda Y, Yamada K. Development of a teicoplanin-nomogram for accurately maintaining correct dosages. J Jpn Soc Hosp Pharm. 2005;41:1267–70.

    CAS  Google Scholar 

Download references

Acknowledgments

Financial support for this study was provided by the Japan Society for the Promotion of Science (17923059).

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Yasuo Takeda.

About this article

Cite this article

Kanazawa, N., Matsumoto, K., Ikawa, K. et al. An initial dosing method for teicoplanin based on the area under the serum concentration time curve required for MRSA eradication. J Infect Chemother 17, 297–300 (2011). https://doi.org/10.1007/s10156-010-0105-1

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10156-010-0105-1

Keywords

  • Teicoplanin
  • Nomogram
  • Loading dose
  • AUC
  • Methicillin-resistant Staphylococcus aureus (MRSA)